Clinical Trial Update: Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 dose-expansion study evaluating a low-dose post-transplant cyclophosphamide/tacrolimus/ruxolitinib regimen for graft-versus-host disease prophylaxis i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Jakafi (ruxolitinib)
• Prograf (Tacrolimus)

Snippet

Sponsor: Hannah Choe, MD | Conditions: Leukemia, Myelodysplasia | Phase 2 | Status: RECRUITING